ONCAlert | Upfront Therapy for mRCC
Latest From ILCA
Second-Line Pembrolizumab Confers Improved OS, PFS in Patients With Advanced HCC
6:00 PM, Sun September 22, 2019
RESORCE Trial Analysis Shows Higher AFP Responses Achieved With Regorafenib in HCC
4:16 PM, Sun September 22, 2019
Expert Speaks to Non-Alcoholic Fatty Liver Disease-Related Mortality and Development of HCC
6:18 PM, Sat September 21, 2019
Safety of Nivolumab/Ipilimumab Combination Confirmed for Advanced HCC
4:52 PM, Sat September 21, 2019
Advice on Decision Making for Frontline Treatment of HCC
8:26 PM, Thu September 20, 2018
Exploring Immunotherapy Combinations for the Treatment of HCC
2:21 PM, Tue September 18, 2018
Cabozantinib Improves Survival in Previously Treated Patients With HBV+ HCC
7:44 PM, Sat September 15, 2018
Recent Advancements for the Treatment of Liver Cancer
6:11 PM, Sat September 15, 2018
Deep, Durable Responses Seen With Atezolizumab Combo For Frontline HCC Treatment
3:43 PM, Sat September 15, 2018
Sequencing Strategies Necessary After Expansion of Therapy Options in HCC
8:38 PM, Fri September 14, 2018
